Age-related macular degeneration (AMD) is a major cause of blindness worldwide and is the leading cause of vision loss and blindness for Americans aged 65 years and older. Diabetic macular edema (DME) and diabetic retinopathy (DR) are complications affecting about 25% of all patients with long-standing type 1 and type 2 diabetes mellitus and are a major cause of significant decrease in vision and quality of life. These retinal degenerative conditions predominantly affect the central macula and are associated with the presence of retinal edema and an aggressive inflammatory repair process that accelerates disease progression. Recent studies suggest that DME, DR, and AMD are conditions characterized by a breakdown of the blood-retinal barrier, inflammatory processes, and an increase in vascular permeability.
Our RELIEF program is an online tool that aims to provide clinicians and patients with up-to-date information on these two common forms of visual impairment due to retinal disease in adults. The development of more targeted therapies has revolutionized the care of patients with AMD, DR, and DME, leading to better control of disease progression and greater improvements in patients’ quality of life. Our goal is to provide information that empowers clinicians and patients to speak openly about treatment decisions and improve the standard of care for patients with conditions affecting their vision.
Thank you for visiting our website. Please explore the Clinician and Patient Toolkit links for cutting-edge information on present and future treatments for conditions affecting the retina.